Physician profile
Muhammad Shakeel
NPI 1851581003
$2,113.12
in general payments reported to CMS, 2019-2025
13 companies · $602 in 2025
The $602 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $100 · 2021: $150 · 2022: $188 · 2023: $418 · 2024: $386 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.29 | 2021-2025 | Teflaro, Dalvance |
| Merck Sharp & Dohme LLC | $291.20 | 2019-2025 | Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.56 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $284.77 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $245.97 | 2025 | Lifevest |
| Pfizer INC. | $106.83 | 2019-2024 | |
| Allergan, INC. | $98.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $76.31 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $63.25 | 2024 | Eliquis |
| Edwards Lifesciences Corporation | $29.00 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $23.94 | 2024 | |
| Glaxosmithkline, LLC. | $17.79 | 2023 | Benlysta |
| Boston Scientific Corporation | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shakeel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.